Stay updated on Taletrectinib ROS1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Taletrectinib ROS1+ NSCLC Clinical Trial page.

Latest updates to the Taletrectinib ROS1+ NSCLC Clinical Trial page
- Check4 days agoChange DetectedVersion 13 adds the Contacts/Locations and Study Status sections to the record history. The update corresponds to Revision: v3.3.4 (2026-01-07).SummaryDifference0.6%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedAdded a footer note 'Revision: v3.3.3'. Removed the 'HHS Vulnerability Disclosure' link and the 'Revision: v3.3.2' note from the footer.SummaryDifference0.2%

- Check53 days agoChange DetectedThe history now shows an added Revision: v3.3.2 and a removed Revision: v3.2.0, reflecting minor metadata updates to the record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoval of a government funding/operating-status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check75 days agoChange DetectedA new version entry has been added to the record history, reflecting an updated Study Status and related fields (e.g., Sponsor/Collaborators, Oversight).SummaryDifference0.1%

- Check89 days agoChange DetectedThe page changes remove the old recruitment status and date (Recruiting, 2024-11-21) and replace them with an updated recruitment status (Active, not recruiting) and updated date stamps (2025-10-16 and 2025-10-14) along with expanded section headers. Interpreting this, the study is currently active but not recruiting participants, and there are new or reorganized sections for study headers and contacts.SummaryDifference4%

Stay in the know with updates to Taletrectinib ROS1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Taletrectinib ROS1+ NSCLC Clinical Trial page.